Newsfeeds - Spark Newswire

8 minute read

Procaps Issues Shareholder Letter And Provides Preliminary FY22 Financial Results And 2023 Guidance; Sees FY22 Revenue $405M-$415M Vs $444.2M Est; Announces $5M+ Share Repurchase Program; Expect To Grow Net Revenues At ~10%+ In 2023

Today, 1:27 PM

Reports Preliminary Financial Estimates for Net Revenue and Adjusted EBITDA for Full Year 2022 Realigns Board of Directors to Focus on Profitable Growth Announces $5M+ Share Repurchase Program Commences

PROC

1 minute read

News

5 Value Stocks In The Healthcare Sector

By Benzinga Insights

Today, 1:27 PM

What are Value Stocks? A value stock traditionally has a lower price when compared to stock prices of…

CGEM

2 minute read

News

Procaps Group Announces Termination Of Acquisition Agreement With Grupo Somar

By Michael Horton

Today, 1:27 PM

Procaps Group, S.A. (NASDAQ:PROC) ("Procaps" or the "Company"), a leading integrated LatAm healthcare and pharmaceutical conglomerate, today announced the termination of its previously-reported

PROC

1 minute read

Procaps Gr Q3 Sales $110.00M

By Michael Horton

Today, 1:27 PM

Procaps Gr (NASDAQ:PROC) reported quarterly sales of $110.00 million which missed the analyst consensus estimate of $123.90 million by 11.22 percent.

PROC

17 minute read

Earnings

Earnings Scheduled For November 14, 2022

By Benzinga Insights

Today, 1:27 PM

Companies Reporting Before The Bell • Opiant Pharma (NASDAQ:OPNT) is estimated to report quarterly loss at $1.49 per share on revenue of $3.68 million.

AAIC

2 minute read

Procaps Group To Acquire Grupo Somar (including Química Y Farmacia, Gelcaps And Related Entities) From Advent International; Potential Net Present Value Between 25%-40% Of Total Purchase Price

By Benzinga Newsdesk

Today, 1:27 PM

Procaps Group (NASDAQ:PROC) ("Procaps"), a leading integrated LatAm healthcare and pharmaceutical conglomerate, today announced it has entered into a definitive agreement to acquire Grupo Somar (including Grupo

PROC

3 minute read

News

Procaps Group Reports Purchase Of Softgel Production Facility, Pharma R&D Center, No Terms Disclosed

By Benzinga Newsdesk

Today, 1:27 PM

Procaps Group (NASDAQ:PROC), a leading integrated international healthcare and pharmaceutical company, today announced the closing of an asset purchase agreement to acquire an 86,000 sq. ft. pharmaceutical production

PROC